Loading patent…
AssigneeThe Penn State Research Foundation
InventorsGavin P. Robertson, Lakshman Segar, Mark Kester, Arati K. Sharma
Estimating the term…
The invention relates to combining targeted therapies with selected chemotherapeutics for the treatment of melanoma. The invention provides a method for inducing apoptosis in a melanoma tumor cell by reducing Akt3 activity, a method for inducing apoptosis in a melanoma tumor cell comprising contacting a melanoma tumor cell with an agent that reduces Akt3 activity to restore normal apoptotic sensitivity to a melanoma tumor cell, allowing a lower concentration of chemotherapeutic agents resulting in decreased toxicity to a patient. Also disclosed is a method for treating a melanoma comprising administering an agent that reduces Akt3 activity and an agent that reduces V599E B-Raf activity, thereby treating a melanoma tumor.
-35. (canceled)
A pharmaceutical composition for treating a melanoma tumor comprising:
The pharmaceutical composition of 49 wherein said peptide acts as a pseudosubstrate for a catalytic domain or a regulatory domain of Akt3.
The pharmaceutical composition of 38 wherein said agent is a peptide that acts as a competitive inhibitor for Akt3.
The pharmaceutical composition of 51 wherein said peptide acts as a competitive inhibitor for a catalytic domain of Akt3.
Dependencies are inferred from the claim text.